NME postmarketing safety reviews are labour-intensive, US FDA finds
This article was originally published in SRA
A US Food and Drug Administration pilot programme that reviewed the postmarketing safety of five new molecular entities identified a total of 22 safety issues for follow-up1. The project took more than 1,000 staff hours but the results showed no strong correlation between the time needed to conduct the analyses and the extent of a drug’s use or number of adverse event reports.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.